Novo Nordisk’s oral semaglutide on par with injectable version in weight loss and safety

An oral ver­sion of No­vo Nordisk’s semaglu­tide helped pa­tients tak­ing the high­est dose lose 15% of their body weight.

It’s on par with No­vo’s We­govy, which is the in­jectable ver­sion of semaglu­tide that is ap­proved for weight loss. We­govy has shown that obese or over­weight pa­tients lost 15% of their weight from a base­line of 105 kg, ac­cord­ing to the FDA la­bel.

In the 68-week Phase III OA­SIS-1 study, No­vo test­ed out es­ca­lat­ing dos­es up to 50 mg of semaglu­tide in over 600 pa­tients who are over­weight or obese, ac­cord­ing to da­ta re­leased at the Amer­i­can Di­a­betes As­so­ci­a­tion’s an­nu­al con­fer­ence on Sun­day night. The study found that par­tic­i­pants tak­ing the 50 mg dose saw a 15.1% body weight re­duc­tion com­pared to 2.4% on place­bo.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN